Targets › CD205
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.
Acts as an endocytic receptor to direct captured antigens from the extracellular space to a specialized antigen-processing compartment (By similarity). Causes reduced proliferation of B-lymphocytes. (UniProt, O60449)
Open in Phaseline: the race on CD205, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Oxford BioTherapeutics | OBT076 anti-CD205 antibody-drug conjugate | CD205 | Phase 1 | Solid Tumor | Dec 2026 |
Solid Tumor (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.